- ABOUT ME
- AREAS OF FOCUS
- EDUCATION & LEADERSHIP
- LOCATIONS & HOSPITALS
- NEWS & PUBLICATIONS
Dr. McGinnis’ introduction to Radiation Oncology occurred when her father underwent radiation treatment for Stage IV rectal cancer, forging a meaningful bond with his radiation oncologist. As her training progressed, she discovered that Radiation Oncology harmonizes her professional passions; encompassing innovative technologies and therapeutics, expert knowledge in anatomy and oncological approaches, dedication to health equity, and rewarding connections with patients.
In addition to standard 3D or VMAT techniques, Dr. McGinnis has been trained on the use of SBRT, MR LINAC, Gamma Knife, proton therapy, and HDR brachytherapy. She has training in using high-dose rate brachytherapy for gynecologic, genitourinary, skin, and breast malignancies.
Dr. McGinnis finds the opportunity to connect and care for patients during a challenging time in their lives is incredibly meaningful. She enjoys sharing her expertise in cancer medicine and when patients teach her about their experiences. She also finds that working in a multi-disciplinary team is an enjoyable and important aspect of providing high quality oncology care.
Growing up in Portland, Dr. McGinnis has always loved the beautiful surroundings and easy access to the rivers, mountains, and beaches nearby. As an adult, she has come to love riding her bicycle around the city and getting to try all of the amazing vegetarian food options. Outside of work, Dr. McGinnis enjoys cycling, backpacking, CrossFit, reading, and board games.
Other Activities
Member, American Society for Radiation Oncology
Member, American Board of Radiology
Member, The Radiosurgery Society
Member, Radiological Society of North America
Member, Society for Women in Radiation Oncology
Member, American Brachytherapy Society (ABS)
Areas of Focus
High Dose Rate (HDR) Brachytherapy
Image-Guided & Intensity Modulated Radiation Therapy (IGRT/IMRT)
Stereotactic Body Radiation Therapy (SBRT/SABR)
Magnetic Resonance-Guided Radiation Therapy (MRgRT/MRLinac)
3D Conformal Radiotherapy
Gynecologic Cancers, including Uterine, Cervical, Vaginal & Vulvar
Head & Neck Cancer
Thoracic Cancers, including Lung, Thymus & Lymphoma
Breast Cancer
Genitourinary Cancers, including Prostate, Bladder & Testis
Gastrointestinal Cancers, including Esophagus, Stomach, Colorectal, Anal, Pancreas & Hepatobiliary
Skin Cancers, including Melanoma, Squamous Cell, BCC & Cutaneous Lymphomas
Benign Conditions treated with Radiotherapy
EDUCATION & TRAINING
Residency, University of Texas MD Anderson Cancer Center Department of Radiation Oncology, Houston, TX, 2023
Internship, Preliminary Medicine, Saint Joseph Hospital, Denver, CO, 2019
Master of Clinical Research, Oregon Health & Science University, Portland, OR, 2018
Doctor of Medicine, Oregon Health & Science University, Portland, OR, 2018
Bachelor of Science, Biology and Evolutionary Anthro, Duke University, Durham, NC, 2012
BOARD CERTIFICATION
Radiation Oncology – Board Eligible
HONORS
Mary Fletcher Heart of Caring Award (2020) – MD Anderson Cancer Center
Medical Student Award for Research (2018) – School of Medicine, Oregon Health & Science University
Induction to Alpha Omega Alpha Honor Society (2017)
RSNA Medical Student Research Grant (2014, 2017)
N.L. Tartar Research Fellowship (2014, 2017) – Oregon Health & Science University Foundation
Franz Stenzel, MD and Kathryn Stenzel Award (2014-2017) – Oregon Community Foundation
Outstanding Medical Student Scholarship (2016) – Oregon Health & Science University
Howard Hughes Medical Institute Medical Research Fellowship (2015)
Research Support Grant (2015) – Collins Medical Trust
NIH Post-baccalaureate Research Fellowship (2012)
Locations
Hospitals Served
- Providence Portland Medical Center
Publications
Shi JJ, McGinnis GJ, Peterson SK, Taku N, Ying-Shiuan C, Yu RK, Wu CF, Mendoza TR, Shete SS, Ma H, Volk RJ, Giordano SH, Shih YCT, Kaiser K, Nguyen DK, Smith, GL. Pilot Study of a Spanish Language Measure of Financial Toxicity in Underserved Hispanic Cancer Patients with Limited English Proficiency. Front Psychol. 2023 June.
McGinnis GJ, Holden S, Yu B, Ransom C, Guidarelli C, De BS, Diao K, Boyce D, Thomas CR Jr, Winters-stone K, Raber J. Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention. Oncotarget. 2022 Nov. PMID: 36441715.
Jacobsen MC, Beriwal S, Dyer BA, Klopp A, Lee S, McGinnis GJ, Robbins J, Rauch GM, Sadowski E, Simiele S, Stafford RJ, Taunk N, Yashar C, Venkatesan AM. Consensus Imaging Recommendations from the Society of Abdominal Radiology and the American Brachytherapy Society. Brachytherapy. 2022 June. PMID: 35725550
McGinnis GJ, Ning MS, Mafuka R, Nsingo M, Chiyapo S, Balang D, Grover S, Cardenas CE, Court LE, Smith GL. Radiation Oncology Practitioner-Reported Benefits and Barriers to Clinical Implementation of an Automated Radiotherapy Treatment Planning Tool: A Multi-Site Survey. J Global Oncol. 2022 May. PMID: 35537104.
Grover S, Ning MS, Bale M, Lichter KE, Shah S, Bvochora-Nsingo M, Chiyapo S, Balang D, McGinnis GJ, Ralefala T, Moloi T, Luckett R, Ramogola-Masire D, Robertson ES, Zetola NM. Chemoradiation versus radiation alone in stage IIIB cervical cancer patients with or without human immunodeficiency virus. Int J Gynecol Cancer. 2021 Jul. PMID: 34312220.
McGinnis GJ, Ning MS, Bvochora-Nsingo M, Chiyapo S, Balang D, Ralefala T, Lin A, Zetola NM, Grover S. Management of head and neck cancers with or without comorbid HIV infection in Botswana. Laryngoscope. 2021 May. PMID: 33098322.
McGinnis GJ, Ning MS, Nitsch PL, O’Reilly MS, McAleer MF, Koong AC, Chang JY. Rapid detection of asymptomatic coronavirus disease 2019 by computed tomography image guidance for stereotactic ablative radiotherapy. J Thorac Oncol. 2020 June. PMID: 32311499.
Pasalic D, McGinnis GJ, Fuller CD, Grossberg AJ, Verma V, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Diefenhardt M, Das P, Subbiah V, Subbiah IM, Jagsi R, Garden AS, Fokas E, Rödel C, Thomas CR Jr, Minsky BD, Ludmir EB. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. Eur J Cancer. 2020 Sep. PMID: 32702645.
McGinnis GJ, Raber J. CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. Immunotherapy. 2017 Sep. PMID: 29338610.
McGinnis GJ, Friedman D, Young KH, Torres ER, Thomas CR Jr, Gough MJ, Raber J. Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model. Oncotarget. 2017 Feb. PMID: 27893434.